Reach Us +1-504-608-2390
Differential Gene Expression In The Thymus To Establish Low Toxicity Chemotherapeutic Agents | 19551
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

7th International Congress on Infectious Diseases

Berlin, Germany

4th International Conference on Mass Spectrometry

Milan, Italy
Share This Page

Differential gene expression in the thymus to establish low toxicity chemotherapeutic agents

3rd International Conference and Exhibition on Clinical & Cellular Immunology

Philip J Lucas, Kirsten M Williams, Jiun Wang and Ronald E Gress

ScientificTracks Abstracts: J Clin Cell Immunol

DOI: 10.4172/2155-9899.S1.017

Thymic recovery can be a rate limiting process in full immunological recovery following chemotherapy. Emerging literature suggests that thymic insufficiency may have significant clinical consequences, exacerbating graft-versus-host disease and compromising the graft-versus-leukemia effect. Data have demonstrated that the thymus is damaged following current transplant preparative regimen, with a disproportionate depletion of UEA+ thymic epithelial cells (TEC). Very little is known about the effects of the individual components of such preparative agents. We have established an array of 25 murine genes expressed throughout the thymus, including UEA+ TEC, Ly51+ TEC and all thymocytes. Using quantitative PCR, we were able to use expression levels from this panel of genes to monitor the effects of chemotherapeutic agents on the thymus. To establish feasibility of this model, we first studied the effect of cyclophosphamide, a common agent in many chemotherapeutic regimens. Using a dose of 120 mg/kg x 2, we found significant changes (p<0.05) in 11 of 23 genes in the TEC populations (2 up and 9 down), as well as, 11 genes in the thymocyte population (11 down). Our data suggests that our current panel of thymic expression genes is capable of detecting changes after treatment with potential thymus altering agents.
Philip J Lucas received his PhD from The George Washington University, Washington, DC in 1991 in Immunology and Molecular Biology and completed his Postdoctoral studies with the Howard Hughes Medical Institute at Washington University School of Medicine in St. Louis, MO. He is currently a Staff Scientist in the Experimental Immunology and Transplantation Branch, NCI, NIH where he studies the effects of stem cell transplantation on thymus.